Peter P. Phildius, Chairman and CEO commented, "Despite our capital constraints we continue our efforts to grow the Company. As previously reported, we are positioning our oral fluid, drugs of abuse product line, Oralscreen, to address the needs of larger employers across several industry sectors. Particularly in the construction vertical market where the incidence of drug abuse has reached as high as 20%, we are beginning to see traction from our sales and marketing efforts."
Mr. Phildius continued, "As we have previously noted, our foam business continues to be negatively impacted by the lack of sales by the new distributor of our Hydrasorb product line. We are working to develop new distribution channels for Hydrasorb and, in addition, we are expanding our customer base in the foam product area to reduce our dependence in the future on our branded Hydrasorb product line."
Avitar, Inc. develops, manufactures and markets innovative and
proprietary products in the oral fluid diagnostic market, disease and
clinical testing market, and customized polyurethane applications used in
the wound dressing industry. Oral fluid diagnostics includes the estimated
$1.5 billion drugs-of- abuse testing market, which encompasses the
corporate workplace and criminal justice markets. Avitar's products include
ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid
test for drugs-of-abuse. Additionally, Avitar manuf
|SOURCE Avitar, Inc.|
Copyright©2007 PR Newswire.
All rights reserved